News

The Australasian Leukaemia & Lymphoma Group (ALLG) is pleased to announce the appointment of Professor Jake Shortt as Chair of the ALLG Scientific Advisory Committee (SAC), effective 1 December 2026.

Professor Shortt will succeed Professor Judith Trotman, who has provided exceptional leadership and strategic guidance as SAC Chair. Under Professor Trotman’s stewardship, the Scientific Advisory Committee has played a critical role in shaping ALLG’s research direction, strengthening its clinical trial portfolio, and fostering scientific excellence across the organisation.

A Distinguished Leader in Blood Cancer Research

Professor Shortt is nationally and internationally recognised for his contributions to the fields of leukaemia, lymphoma, myelodysplasia, and myeloma. He is Clinical Director of Haematology at Monash Health and Head of the Department of Haematology at Monash University’s School of Clinical Sciences.

He also leads the Blood Cancer Therapeutics Laboratory, where his translational research focuses on developing novel therapies for blood cancers and accelerating their progression from laboratory discovery to clinical application. His commitment to bridging scientific innovation with patient care has established him as a leading figure in haematology research.

A Strong History of Leadership with ALLG

Professor Shortt has a long-standing association with ALLG and has played an important role in shaping the organisation’s scientific and research agenda. He served on the Scientific Advisory Committee from 2016 to 2023, including terms as Chair of the Laboratory Sciences Committee and Deputy Chair of the Scientific Advisory Committee.

Throughout his involvement with ALLG, Professor Shortt has championed translational and laboratory science initiatives, helping strengthen the integration of laboratory discoveries into clinical research programs. His deep understanding of ALLG’s mission and strategic priorities positions him well to lead the Scientific Advisory Committee into its next phase.

Commenting on the appointment, ALLG Board Chair David Fagan said:

“We are delighted to welcome Professor Jake Shortt as the next Chair of the Scientific Advisory Committee and as Director to the Board. Jake brings exceptional scientific expertise, proven leadership, and a deep commitment to collaborative research. His vision and experience will be invaluable as ALLG continues to advance innovative clinical trials and translational research that improve outcomes for people affected by blood cancers.”

Recognising Professor Judith Trotman’s Outstanding Contribution

Professor Shortt succeeds Professor Judith Trotman, who has provided exceptional leadership and strategic guidance throughout her tenure as SAC Chair.

“It is a great pleasure to pass the privilege of this Chair role on to such a talented clinician scientist. A critical thinker, clear communicator and strong mentor, Professor Shortt will balance science and strategy to further the research outputs and global impact of our cooperative trials group.”

Under Professor Judith Trotman’s stewardship, the Scientific Advisory Committee has played a critical role in shaping ALLG’s research direction, strengthening its clinical trial portfolio, and fostering scientific excellence across the organisation. Her dedication has helped position ALLG as a leader in blood cancer research across Australasia.

ALLG extends its sincere gratitude to Professor Trotman for her invaluable contribution and commitment to the organisation. To ensure a seamless transition, Professor Shortt and Professor Trotman will work closely with ALLG and the Scientific Advisory Committee in the lead-up to 1 December 2026, maintaining continuity and supporting the delivery of ALLG’s strategic scientific priorities.

ALLG looks forward to Professor Shortt’s leadership as the Scientific Advisory Committee continues to guide the organisation’s research agenda and foster the development of innovative studies that improve the lives of patients with blood cancers.